Mutations in PI3K/AKT/mTOR pathway were reported frequently in advanced thyroid cancers (PDTC or ATC) especially in metastatic or recurrent cases, and also in follicular thyroid carcinomas [18,19]. This evidence concerns the gene MTOR and thyroid cancer.